News & Updates

In the treatment of patients with acute coronary syndrome receiving dual antiplatelet therapy during the acute phase, oral rivaroxaban appears to compare favourably with subcutaneous enoxaparin in terms of bleeding and major adverse cardiovascular event risks, according to a study.

Use of moderate to high-intensity statin (MHIS) following myocardial perfusion imaging (MPI) results in fewer major adverse cardiovascular events (MACE) and is independently predictive of 24-month MACE among patients with normal stress MPI and coronary artery calcium (CAC) score >300, a Singapore study has shown.

Compared with standard dual antiplatelet therapy (DAPT), P2Y12 inhibitor monotherapy after 1- to 3-month DAPT results in similar rates of fatal and ischaemic events, as well as lower major bleeding risk, regardless of percutaneous coronary intervention (PCI) complexity, according to a study.

Twice-yearly maintenance dosing of inclisiran reduces atherogenic lipoproteins for primary prevention of patients with elevated LDL-C* despite statin use, according to the analysis of the primary prevention cohort from the ORION-11 trial.

Mental health conditions (MHCs) befall many cardiologists globally, which may lead to substantial adverse effects on their professional life, reveals a study.

Coronary artery disease appears to be common among women with a history of adverse pregnancy outcomes, including those estimated to be at low risk of cardiovascular disease, according to a study.